Objective Our retrospective study is aimed to compare the effect and the adverse reaction of TNP(paclitaxel liposome +nedaplatin +tegafur)and PF(fluorouracil +cisplatin)in the treatment of head and neck squamous cell carcinoma(SCCHN).Methods Clinical data of patients with SCCHN received treatment at our hospital from 2009 to 2014 was retrospectively analyzed .Patients were divided into PF group and TNP group according to the treatment prescription .The general data,clinical features,treatment and the adverse reactions of the two groups were compared .Results A total of 54 patients was retrospective analyzed ,including 27 patients in TNP group and 27 in PF group.There was no significant differences in clinical data between the two groups .There was no significant differences in the location of the tumor ,clinical stage and differentiation degree between the two groups.The curative effect of TNP group was significantly ameliorated than the PF group .The incidence of gastro-intestinal reaction in TNP group was obviously lower than in PF group .There was no significant differences in the other adverse reactions .Conclusion In the treatment of SCCHN , TNP regimen is more effective than PF regi-men,and the incidence of gastrointestinal adverse reaction during the treatment is lower .

Objective To analyze the long-term results of rituximab combined with whole brain radiotherapy and 3-dimentional conformal radiotherapy (3D-CRT) in treatment of patients with primary central nervous system lymphoma (PCNSL). Methods 23 postoperative patients younger than 60 years old were treated. Whole brain radiotherapy with dose of 32.4 Gy were performed and lesions were followed by 3D-CRT with dose of 18 Gy.A dose of rituximab (375 mg/m2) was infused on day 1 (once a week for six weeks).The overall survival was analyzed by using Kaplan-Meier.Results 19 patients(82.6 ％) was complete remission 3 patients (13.0 ％) was part remission,14 patients (60.9 ％) was progression-free survival was 26 months (17-34 months). The overall survival was 40 months (29-55 months). Toxicity was moderate without grade 3-4 neurotoxicity toxic events. Conclusions Radiotherapy (whole brain radiotherapy with sequential 3D-CRT)combined with rituximab seems to yield substantial long-term survival with moderate toxicity for the treatment of the younger patients with PCNSL.